Anthony F. Lever

TL;DR: Long-term use of ACE inhibitors may protect against cancer; the status of this finding is more that of hypothesis generation than of hypothesis testing; randomised controlled trials are needed.

TL;DR: Although hydralazine inhibits the pressor and cardiac effects of angiotensin II, suggesting a pressor mechanism for the cardiac change, it does not inhibit structural vascular change, which suggests that at least part of the effect has a non-pressor mechanism.

TL;DR: It is demonstrated that a 4-week period of ACE inhibitor treatment in young SHR is sufficient to prevent the full expression of genetic hypertension and cardiovascular hypertrophy and that angiotensin II might be important in the development of hypertension in this model, its role in later life being less important.

TL;DR: Recommendations on blood pressure thresholds for intervention, on non-pharmacological and pharmacological treatments, and on treatment goals are made on anti-hypertensive treatment.

TL;DR: A working party of the British Hypertension Society as mentioned in this paper reviewed available intervention studies on anti-hypertensive treatment and made recommendations on blood pressure thresholds for intervention, on non-pharmacological and pharmacological treatments, and on treatment goals.